Physician profile
Jose Antonio Menajovsky
NPI 1720231459
$19,375.85
in general payments reported to CMS, 2019-2025
24 companies · $2,978 in 2025
The $2,978 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $2,695 · 2021: $2,764 · 2022: $2,977 · 2023: $2,967 · 2024: $3,498 · 2025: $2,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,430 · Education: $12.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,430.44 |
| Education | $12.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,448.78 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $4,012.90 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Insmed, INC. | $1,782.13 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $1,690.47 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $1,631.67 | 2019-2025 | Dificid, Pifeltro, Zerbaxa |
| Abbvie INC. | $1,056.47 | 2019-2025 | |
| Melinta Therapeutics, LLC | $892.31 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Theratechnologies INC. | $683.24 | 2019-2025 | Egrifta, Trogarzo |
| Paratek Pharmaceuticals, INC. | $645.09 | 2019-2025 | Nuzyra |
| Shionogi INC | $430.72 | 2023-2025 | Fetroja |
| Janssen Products, Lp | $198.99 | 2020-2022 | |
| Vyera Pharmaceuticals, LLC | $183.68 | 2020-2021 | |
| Allergan, INC. | $165.73 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $126.75 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $110.02 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $82.89 | 2019-2025 | |
| Mylan Specialty L.P. | $50.13 | 2019 | |
| Janssen Scientific Affairs, LLC | $39.78 | 2022-2023 | Symtuza |
| Mayne Pharma Commercial LLC | $36.16 | 2021 | |
| Nabriva Therapeutics, Plc | $32.05 | 2020 | |
| Organogenesis INC. | $26.23 | 2025 | Novachor |
| Takeda Pharmaceuticals U.S.A., INC. | $18.40 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Menajovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.